ARBUTUS BIOPHARMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.86 USD | -1.04% |
|
+0.70% | +14.40% |
| May. 09 | Whitefort Capital Management Engages with Arbutus Biopharma | CI |
| May. 02 | Transcript : Arbutus Biopharma Corporation, Q1 2024 Earnings Call, May 02, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 9.04M 6.62M | Sales 2025 * | 8.08M 5.92M | Capitalization | 744M 545M |
|---|---|---|---|---|---|
| Net income 2024 * | -98M -71.78M | Net income 2025 * | -102M -74.71M | EV / Sales 2024 * | 82.4 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 92.1 x |
| P/E ratio 2024 * |
-7.31
x | P/E ratio 2025 * |
-7.27
x | Employees | 73 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Arbutus Biopharma Corporation
More recommendations
More press releases
| 1 day | -1.04% | ||
| 1 week | +0.70% | ||
| Current month | +4.76% | ||
| 1 month | -1.72% | ||
| 3 months | -1.72% | ||
| 6 months | +52.13% | ||
| Current year | +14.40% |
1 week
2.79
2.96
1 month
2.632.96
Current year
2.213.29
1 year
1.693.29
3 years
1.696.50
5 years
0.829.02
10 years
0.8229.93
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 17-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 59 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 2.86 | -1.04% | 475,466 |
| 24-05-13 | 2.89 | +0.35% | 367,246 |
| 24-05-10 | 2.88 | -2.04% | 697,958 |
| 24-05-09 | 2.94 | +3.52% | 688,712 |
| 24-05-08 | 2.84 | 0.00% | 503,997 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotes
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patientsâ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.904
CAD
Average target price
6.029
CAD
Spread / Average Target
+54.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.40% | 545M | |
| -1.54% | 89.37B | |
| +2.76% | 40.65B | |
| -12.32% | 32.81B | |
| +52.41% | 25B | |
| -17.39% | 15.29B | |
| -42.45% | 11.61B | |
| -10.48% | 11.49B | |
| +6.14% | 8.98B | |
| -7.72% | 8.23B |
- Stock Market
- Equities
- ABUS Stock